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Abstract
Papillary carcinoma of the thyroid (PTC) is the commonest thyroid cancer. In the recent decades an obvious
increase in the incidence of PTC has occurred. The pathological diagnosis of PTC is usually an easy diagnosis in
the majority of cases. However since the introduction of follicular variant of PTC and the wide threshold range
in interpretation of the clearly set pathological criteria for diagnosis of PTC, between pathologists including
experts, the diagnosis in some cases became quite difficult. Unfortunately some cases are unjustifiably over-called
as follicular variant of PTC as a result of the wide inter observable variability between pathologists, including
thyroid pathologists.
Ancillary studies such as immmunohistochemistry may be helpful, but till now there is no 100% consistent
marker(s), that distinct between PTC and other follicular thyroid lesions and tumors.
We assessed expression of antibodies against CD56, CK19, P63 and E-Cadherin in PTC and other follicular
thyroid lesions and neoplasms. A total of 175 cases were studied. The neoplastic cases included 75 carcinomas
(72 papillary, 2 follicular, 1 Hurthle cell) and 35 adenomas (32 follicular and 3 Hurthle cell). The non-neoplastic
thyroids included 65 cases, (25 nodular hyperplasia, 5 thyrotoxic hyperplasia (Grave's disease), 19 lymphocytic
thyroiditis and 6 Hashimoto's thyroiditis). All cases were evaluated by immunohistochemistry for the expression
of the above mentioned markers. The markers' patterns and intensities of staining were scored. Positive
expression of the markers equal or >10% of the follicular epithelium within the tumor or lesional cells was
considered positive. An expression of <10% was considered to be negative.
Our results showed CD56 positive in all the lesions and tumors except for PTC in all cases (100%). CD56 was
negative in all PTC cases (100%). CK 19 showed positive expression in PTC accounting for 85% of cases and in
26% of non PTC lesions/tumors. P63 showed selective focal positivity in PTC cases, in contrast to other non PTC
lesions/tumors. P63 expression was in 70% of cases of PTC and was consistently absent in all the non PTC cases.
E-Cadherin showed consistent non discriminatory expression in all cases included in the study.
We concluded that a panel consisted of CD56, CK19 and P63 is of value in distinction of PTC from other thyroid
follicular lesion. P63 is a specific but less sensitive marker for PTC than CK19. CD56 is more specific and sensitive
marker than CK19, however it is a negative rather than a positive marker for PTC. E-Cadherin is of no value in
the diagnosis of thyroid follicular lesions/tumors. We recommend application of a panel composed of CK19, P63
and CD56 by a group of expert thyroid pathologists on a large series of follicular malignant thyroid neoplasms of
uncertain malignant.
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Introduction
Papillary thyroid carcinoma (PTC) is the commonest thy-
roid cancer and through the recent decades a marked
increase in its incidence has occurred. Such increase
reflects true increase in incidence of PTC with a minor
component of over diagnosis of PTC. It is clear that some
cases do raise controversy as being PTC or non PTC. For
example follicular adenoma and follicular variant of PTC,
when some of the nuclear diagnostic criteria for PTC are
occasionally present. Unfortunately such controversy
exists between expert thyroid pathologists. Inter observer
disagreements among pathologists are welldocumented
[1]. Eight American and Japanese pathologists had only a
62% diagnosticagreement of 21 thyroid nodules [2]. It
should be noted that these cases represent a minority of
cases and commonly represented by follicular variant of
PTC (as mentioned) or PTC arising in a setting of Hashi-
moto's thyroiditis. Although these cases are minority of
cases, labeling patients with cancer and their over man-
agement is unacceptable, even though it protects the
pathologists from facing an under diagnosed PTC with
future metastasis. Despite that the diagnostic criteria for
PTC have been established for more than 50 years, [3,4] it
seems that its application, especially as regards quantiza-
tion is still not fully established.
Up till today the gold standard for diagnosis of follicular
thyroid lesions particularly PTC is histology. Some of the
ancillary studies as immunohistochemistry and molecular
techniques may be helpful, but none of them is conclu-
sive. Hence the diagnosis of PTC in some cases still subjec-
tive with Inter observer variation between expert thyroid
pathologists that varies between benignity and malig-
nancy on the same case.
CD56 is a neural cell adhesion molecule; hence its expres-
sion may affect the migratory capability of tumor cells.
Hence it is not surprising that loss of CD56 correlates with
metastatic potentials and poor prognostic outcome in
some malignancies [5,6].
P63, a p53-homologue nuclear transcription factor that is
located on 3q27 and encodes six different isoforms, which
harbor either trans-activating or negative dominant effects
on p53 reporter genes. P63 tumor suppressing properties
are disputable and mutations in this gene are rather rare
in human malignancies [7,8]. It is consistently expressed
in basal, squamous and myoepithelial cells such as in
basal cells of the prostate acini and ducts, myoepithelial
cells of the breast and squamous cell carcinoma [7-11].
Cytokeratin polypeptide 19 (CK19) is a type I intermedi-
ate filament protein an is the smallest known keratin and
is remarkable in that, contrary to all other keratins, it does
not have a designated partner for the formation of fila-
ments, implying that regulation of its expression is differ-
ent from other keratin-encoding genes [12]. Cytokeratin
19 concentrate at sarcomeres of striated muscle and copu-
rify with the dystrophinglycoprotein complex, perhaps
through the interaction of the cytokeratin with the actin-
binding domain of dystrophin. In vitro studies showed
that dystrophin binds directly and specifically to CK19
[13]. CK19 is synthesized in simple and stratified epithe-
lia. E-cadherin is a molecule involved in adhesion
between epithelial cells that seems to have a protective
role in cancer, since its loss is associated with tumor pro-
gression and metastases formation in a series of different
cancers [14].
We evaluated the diagnostic value of proteins expressions
using antibodies against CD56, P63, CK19 and E-Cad-
herin in normal follicular thyroid epithelium, follicular
thyroid lesions, and follicular thyroid neoplasms. Our
aim was to study the applicability of difference in these
markers' expressions that distinguish PTC, including the
follicular variant from other follicular thyroid lesions and
neoplasms, provided that the right morphological and
clinical features are fulfilled.
Methods
Thyroid gland lesions and tumors from 1999 to 2007
were searched through the Anatomic Pathology database
and the electronic patients' charts at Thunder Bay
Regional Health Sciences Center and Hamilton Health
Sciences Center.
Demographic information, clinical data, tumor stage,
treatment, and follow up were reviewed. Cases were
reviewed by two pathologists (SA and DD). For the diag-
nosis of PTC, we followed the same histological criteria
applied to the diagnosis of PTC as those proposed by
Chan JKC [15], which are divided into major and minor
features. The major features include: 1. Nuclei are ovoid
rather than round; 2. Nuclei are crowded, often manifest-
ing as lack of polarization in the cells that line a follicle; 3.
Nuclei show a clear or pale chromatin pattern; 4. Psam-
moma bodies are found. If one of the 4 features is lacking,
4 or more of the following subsidiary features may occur:
1. Presence of abortive papillae; 2. Predominantly elon-
gated or irregularly shaped follicles; 3. Dark-staining col-
loid; 4. Presence of rare nuclear pseudoinclusions; or 5.
Multinucleated histiocytes in the lumens of follicles.
The cases diagnosed as Hürthle cell tumors/carcinomas
were composed of greater than 75% oncocytic cells show-
ing moderate to abundant eosinophilic granular cyto-
plasm as proposed in an earlier study [16]. Adenomas
were defined as completely encapsulated follicular or
Hürthle cell tumors with homogeneous architecture andDiagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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morphology, lacking nuclear features of PTC and without
capsular and vascular invasion [16].
As per the local surgical pathology protocols, submitted
representative tissue sections from resections specimens
were routinely processed and embedded in paraffin. In
cases which show a grossly distinct nodule, the nodule is
submitted in toto. Sections 2–3 μ were stained for immu-
nohistochemistry with a standard avidin-biotin complex
method using antibodies against CD56, P63, CK19 and E-
Cadherin (table 1). Results of immunostains were
assessed by two pathologists (DD and SA), and a consen-
sus regarding controversial cases was reached at the dou-
ble-headed microscope. Evaluation of the
immunohistochemical staining was performed by light
microscopy using a 10× objective lens with the selective
use of a 20–40× objective lens for confirmation. A positive
membranous expression with or without cytoplasmic
taining in 10% or more of neoplastic cells qualified the
case as "positive (+)" for CD56, E-Cadherin and CK19.
Any nuclear P63 staining is accounted as positive expres-
sion of P63. Negative cases for P63 are that shows zero
nuclear staining for P63 in the lesional/neoplastic cells.
Immunohistochemistry was performed on 4 m thick sec-
tions using the labeled streptavidin-biotin peroxidase
complex system (LSAB2) in a Dako Autostainer (Dako,
Carpinteria, CA, USA).
Results
Out of the 203 cases of thyroid resections retrieved, a total
of 185 cases were included in the study and all were
stained for antibodies against CD56, P63, CK19 and
ECadherin. A total of 18 cases were excluded as these rep-
resented medullary (10 cases) and anaplastic (4 cases)
thyroid carcinomas, those classified as follicular neo-
plasm of uncertain malignant potential (3 cases) or
caused controversy during review regarding diagnosis (1
case). The 185 cases included 175 cases of follicular
lesions and neoplasms and 10 cases of normal thyroids
from radical laryngectomies for laryngeal squamous cell
carcinomas. The 175 follicular lesions and neoplasms
included 75 carcinomas (72 papillary, 2 follicular, 1
Hurthle cell) and 35 adenomas (32 follicular and 3
Hurthle cell).
The PTC included 15 classic, 23 follicular, 27 micropapil-
lary (24 follicular micropapillary and 3 classic micropap-
illary), 2 Hurthle cell (oxyphilic), one columnar cell, 2
encapsulated and 2 tall cell variants. None of the cases of
PTC was diffuse sclerosing, cribriform, trabecular, muco-
epidermoid, PTC with nodular fasciitis-like stroma or
dedifferentiated PTC variant. Nine cases of PTC (5 from
follicular variant, 1 from columnar variant and 3 from
classic variant) showed metastatic cervical lymph nodes
during presentation or follow up. In both instances metas-
tasis was documented through pathological examination.
Cases of PTC did not show another site of metastasis other
than cervical lymph nodes.
The non-neoplastic thyroids included 65 cases, (25 nodu-
lar hyperplasia, 5 thyrotoxic hyperplasia (Grave's disease),
19 lymphocytic thyroiditis and 6 Hashimoto's thyroidi-
tis). Immunohistochemical results.
The expression of CD56 proteins was diffuse and strong
within all thyrocytes except for all cases of PTC (Figure 1,
Figure 2, Figure 3, Figure 4, Figure 5 and Figure 6), includ-
ing the encapsulated, follicular and microcarcinoma vari-
ants.
Out of the 175 cases included in the study, only the cases
of PTC (including the encapsulated, follicular (Figure 3,
Figure 4), and microcarcinoma variants and those occur-
ring in the setting of Hashimoto's thyroiditis (Figure 5,
Figure 6) showed absent CD56 expression. Such finding
was consistent in all the cases and showed no difference
with different tumor morphological variant or tumor
stage. The metastatic deposits of PTC within the lymph
nodes showed absent CD56 expression, as seen in their
thyroid primaries. The surrounding non-lesional thyro-
cytes showed identical CD56 staining properties.
Within individual benign group/normal thyrocytes and
non-PTC lesions/tumors, CD56 expression showed con-
Table 1: Properties of immunhistochemical antibodies used in the study
Primary Antibody Marker/Clone Supplier Mono (M) Poly (P) Dilution Antigen Retrieval
CD56 Clone: 123C3 Zymed
Invitrogen Corp. (USA)
M 1/100 pH 9.0
E-Cadherin Clone: NCH-38 Dako
USA
M 1/100 pH 9.0
Cytokeratin 19 Clone RCK108 Dako
USA
M 1/50 Enzyme
Proteinase K
P63 Clone: 4A4 Dako
USA
M 1/100 pH 9.0Diagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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sistently strong diffuse expression with no difference
between different subgroups, including hyperplasia, thy-
roiditis (Figure 7, Figure 8), adenomas (Figure 9, Figure
10) and non PTC carcinomas (Figure 11, Figure 12). In all
cases of the non-PTC group, the CD56 expression was
membranous, crisp and diffuses involving 100% of the
thyrocytes, in the lesion.
Within the PTC group, occasional CD56 positive cells
were identified. In all cases, these cells were located at the
tumor non-tumor interface i.e. at the periphery of the
PTC. In all the PTC cases the tumors centers were com-
pletely devoid of any CD56 staining (0%). For all the
cases of PTC, CD56 expression in individual cells did not
exceed 5% of cells all at the periphery. To us these cells
perhaps may represent the infiltrative tumor nontumor
interface and may merely be residual non-tumor cells. We
pointed out a <10% cut of for recording negative CD56
expression, to avoid the future dilemma of lack of quanti-
zation. It worth mentioning that, this occasional CD56
positive cells located at the tumor periphery (interface)
were present in 6/15 of the classic, 20/23 of the follicular,
15/27 of the micro-papillary and of the 2/2 tall PTC vari-
ants. In the remaining PTC variants included in the study,
CD56 expression was absent in all individual cells, cen-
trally and peripherally (0%).
P63 showed selective focal positivity in PTC cases (Figure
13, Figure 14, Figure 15), in contrast to other non-PTC
lesions/tumors (Figure 16, Figures 17, Figure 18). P63
Follicular variant papillary carcinoma CD56 Figure 4
Follicular variant papillary carcinoma CD56.
Classic papillary carcinoma CD56 Figure 2
Classic papillary carcinoma CD56.
Classic papillary carcinoma H&E Figure 1
Classic papillary carcinoma H&E.
Follicular variant papillary carcinoma H&E Figure 3
Follicular variant papillary carcinoma H&E.Diagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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expression was in 70% of cases of PTC and was consist-
ently absent in all the non-PTC cases.
CK 19 showed positive expression in PTC (Figure 19, Fig-
ure 20, Figure 21) and absent expression in non PTC
lesions (Figure 22, Figure 23, Figure 24). However, CK19
expression accounted for 85% of cases of PTC and in 26%
of cases of non-PTC lesions/tumors.
E-cadherin showed consistent non-discriminatory expres-
sion in all cases included in the study (Figure 25, Figure
26, Figure 27, Figure 28, Figure 29, and Figure 30).
Discussion
CD56 is a homophilic binding glycoprotein of the Ig-
superfamily in which its antibody targets an isoform of
the neural cell adhesion molecule (NCAM) and is
expressed normally in NK cells, activated T cells, large
granular lymphocytes, specific endocrine, and brain tissue
[17,18]. The protein itself is believed to regulate cell
motility, homophilic binding between neurons, stimula-
tion of neurite outgrowth, in addition, fasciculation [19].
Since cell migration only takes place during development,
wound healing, and tumor invasion, it should be noted
that previous studies have shown that the expression of
the gene reduces specific tumor invasion [20-22]. CD56 is
present on follicular epithelial cells of the normal thyroid
[23,24].
Thyrotoxicosis CD56 Figure 8
Thyrotoxicosis CD56.
Papillary carcinoma in the setting of Hashimoto thyroiditis  CD56 Figure 6
Papillary carcinoma in the setting of Hashimoto thyroiditis 
CD56.
Papillary carcinoma in the setting of Hashimoto thyroiditis  H&E Figure 5
Papillary carcinoma in the setting of Hashimoto thyroiditis 
H&E.
Thyrotoxicosis H&E Figure 7
Thyrotoxicosis H&E.Diagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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One of the most frequent difficulties in thyroid pathology
is differentiating follicular variant of PTC from follicular
adenoma. The inter observable variability in this area is
well recognized. The differentiation is critical for the treat-
ment and long-term management of the tumors. Despite
the universal recognition of this variant, it is clearly lack-
ing the minimal histological definition of the follicular
variant of PTC. Instead of setting an objective minimal
histological definition, in terms of field size or number of
nuclei with PTC features, the literature resorts to an atypi-
cal category and introduces the term "well-differentiated
tumor of uncertain malignant potential [25]." This term
encompasses encapsulated tumors that have only "minor
nuclear changes of the type seen in typical PTC. The prob-
lem with this term is that it really did not solve the inter
observable variability between pathologists concerning
the diagnosis of the follicular variant of PTC. Instead, it
allowed safe expression of differences in opinion but cer-
tainly increased the chances of over-call and over-treat-
ment of the follicular variant of PTC. Unfortunately, the
immunoprofile of follicular derived lesions and neo-
plasms show some overlap and to the best of our knowl-
edge, no single marker or even panel is 100% sensitive
and 100% specific for PTC. Hence, the use of immunohis-
tochemistry in the diagnosis of the follicular variant of
PTC has to be used with extreme caution. A ecent study
has investigated the expression of NCAM (CD56) in tissue
sections of 61 cases of papillary carcinoma and in 14
lymph node metastases using immunohistochemistry
[26]. In this study, low or absent expression of CD56 was
Hurthle cell carcinoma CD56 Figure 12
Hurthle cell carcinoma CD56.
Follicular adenoma CD56 Figure 10
Follicular adenoma CD56.
Follicular adenoma H&E Figure 9
Follicular adenoma H&E.
Hurthle cell carcinoma H&E Figure 11
Hurthle cell carcinoma H&E.Diagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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noted in PTC using immunohistochemistry and PCR [26].
In the current study, CD56 was extremely useful in the dis-
tinction between PTC, including the follicular variant and
other follicular lesions/neoplasms, as well as PTC mim-
ickers' such as Hashimoto and lymphocytic thyroiditis
and follicular adenoma.
We point out that we excluded those cases (4 cases), that
we disagreed upon and those were diagnosed as well-dif-
ferentiated follicular neoplasm of uncertain malignant
potential. The rational behind their exclusion is that those
cases are rare and highly controversial, and perhaps a large
series of such cases should be evaluated by a group of
experts in regards to the diagnosis and applicability of
CD56, P63, E-cadherin and CK19. Our study shows that
within the thyroid gland, the use of an immunohisto-
chemical panel formed of CD56, E-cadherin, and P63 is
extremely helpful in selecting cases of PTC from other fol-
licular cell-derived thyroid lesions/tumors, with 100%
sensitivity and 100% specificity. However, this is certainly
not applicable outside of the thyroid gland, i.e. within
metastatic sites.
Hence, we suggest that immunohistochemistry using this
panel is helpful in the diagnosis of PTC including the fol-
licular variant of PTC. E-Cadherin immunhistochemistry
is noncontributory.
Thyrotoxicosis P63 Figure 16
Thyrotoxicosis P63.
Follicular variant papillary carcinoma P63 Figure 14
Follicular variant papillary carcinoma P63.
Classic papillary carcinoma P63 Figure 13
Classic papillary carcinoma P63.
Papillary carcinoma in the setting of Hashimoto thyroiditis  P63 Figure 15
Papillary carcinoma in the setting of Hashimoto thyroiditis 
P63.Diagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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Conclusion
Lack of CD56 expression in follicular cell-derived PTC is
consistent, specific, and extremely sensitive. P63 is specific
but less sensitive for diagnosing PTC. CK19 is lessspecific
than both of the previously mentioned markers are, how-
ever it is more sensitive than P63 but less sensitive than
CD56. E-cadherin is of no value in the diagnosis of PTC
and differentiating it from other follicular lesions/neo-
plasm.
Using an immunohistochemical panel formed of CD56,
P63 and CK19 in the diagnosis of PTC, particularly follic-
ular variant, is extremely useful. Evaluation of CD56 and
P63 immunohistochemical expression by a group of
expert thyroid pathologists, on a larger series, especially
those included in the categories of follicular neoplasm of
uncertain malignant potential and follicular carcinomas,
may provide a more objective diagnosis of PTC.
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Follicular variant papillary carcinoma CK19 Figure 20
Follicular variant papillary carcinoma CK19.
Hurthle cell carcinoma P63 Figure 18
Hurthle cell carcinoma P63.
Follicular adenoma P63 Figure 17
Follicular adenoma P63.
Classic papillary carcinoma CK19 Figure 19
Classic papillary carcinoma CK19.Diagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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Hurthle cell carcinoma CK19 Figure 24
Hurthle cell carcinoma CK19.
Thyrotoxicosis CK19 Figure 22
Thyrotoxicosis CK19.
Papillary carcinoma in the setting of Hashimoto thyroiditis  CK19 Figure 21
Papillary carcinoma in the setting of Hashimoto thyroiditis 
CK19.
Follicular adenoma CK19 Figure 23
Follicular adenoma CK19.Diagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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Thyrotoxicosis E-Cadherin Figure 28
Thyrotoxicosis E-Cadherin.
Classic papillary carcinoma E-Cadherin Figure 25
Classic papillary carcinoma E-Cadherin.
Follicular variant papillary carcinoma E-Cadherin Figure 26
Follicular variant papillary carcinoma E-Cadherin.
Papillary carcinoma in the setting of Hashimoto thyroiditis E- Cadherin Figure 27
Papillary carcinoma in the setting of Hashimoto thyroiditis E-
Cadherin.Diagnostic Pathology 2008, 3:5 http://www.diagnosticpathology.org/content/3/1/5
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